Cannabis Terpenes Directly Activate Cannabinoid Receptors, Supporting the Entourage Effect

Multiple cannabis terpenes produced dose-dependent activation of both CB1 and CB2 receptors, reaching 10-60% of THC's maximal activation. Terpenes showed lower efficacy but equivalent or even improved potency compared to THC. At CB2, multiple terpenes reached clinically relevant effect levels at concentrations equal to or lower than THC. Different terpenes showed selectivity between the two receptors.

Xenopus oocyte functional expression system measuring GIRK currents as a readout for CB1 and CB2 receptor activation by 16 individual cannabis terpenes and terpene mixtures.

This provides direct molecular evidence for the "entourage effect" hypothesis. Terpenes are not just aroma compounds; they are partial agonists at the same receptors THC targets. Their selectivity between CB1 and CB2 means different terpene profiles could produce different therapeutic effects.

The cannabis industry has long marketed different strains by their terpene profiles, but the scientific evidence for terpenes having cannabinoid activity has been limited. This study strengthens the case that terpene composition meaningfully affects the pharmacological profile of cannabis products.

In vitro expression system may not perfectly replicate receptor activation in the brain. Terpene concentrations achievable in the brain after cannabis consumption are uncertain. Functional significance of 10-60% activation relative to THC needs further investigation.